Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and remains the leading cause of end-stage renal disease (ESRD) worldwide.
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...
Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...
Aging is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a ...
Karan Arora, senior vice president of advanced assays, AI, and pharma services at Leica Biosystems outlines the critical role ...